Noida-headquartered pharmaceutical firm Jubilant Pharmova reported a 45.09% year-on-year decline in consolidated profit after tax (PAT) attributable to owners to ₹56.50 crore for the quarter ended June 30, 2026, compared with ₹102.90 crore in the year-ago period. According to reports from Business Standard, the decline came despite a 18.21% increase in revenue from operations to ₹2,221.10 crore from ₹1,878.90 crore a year earlier. EBITDA fell 14.4% year-on-year to ₹248 crore, from ₹289.6 crore, while the EBITDA margin stood at 11.1%, compared with 15.2% in the corresponding quarter last year. The company's consolidated EBITDA for the quarter stood at ₹268 crore, with year-over-year margin pressure attributed to temporary unavailability of high-margin SPECT products and higher operating expenses including remediation costs at the CMO Montreal facility. As per The Economic Times, the reported profit decreased YoY due to lower operating profitability and increase in depreciation for Line 3 in Spokane, with total income jumping 18% to ₹2,249 crore against ₹1,913 crore in Q1FY26.
On a sequential basis, PAT attributable to owners fell 52.72% from ₹119.3 crore in the March quarter to ₹56.50 crore, while revenue from operations declined 2.65% from ₹2,290 crore in the preceding quarter to ₹2,221.10 crore. As reported by Business Standard, the company attributed the sequential decline to revenue at CDMO Sterile Injectables being lower quarter-on-quarter due to a planned maintenance shutdown, although the business recorded strong year-on-year growth. The sequential EBITDA decline was primarily due to the temporary unavailability of high-margin SPECT products and negligible third-party revenues. According to The Economic Times, the profit decline was attributed to weaker operating profitability and higher depreciation, while strong growth across segments, led by CDMO Sterile Injectables, boosted revenue.
The company's Radiopharma business recorded revenue of ₹1,022 crore, up 18% year-on-year. Within the segment, Radiopharmaceuticals revenue rose 19% to ₹322 crore, while Radiopharmacies revenue increased 17% to ₹700 crore. According to The Economic Times, Radiopharmaceuticals Q1FY27 revenue grew by 19% to ₹322 crore and EBITDA for the period stood at ₹110 crore, with EBITDA margins decreasing YoY due to unavailability of certain SPECT products. By H2FY27, all the SPECT Radiopharmaceutical products are expected to be available. Radiopharmacy Q1FY27 revenue grew by 17% YoY to ₹700 crore on the back of an increase in volume from certain PET products, with EBITDA growing by 19% to ₹12 crore. Allergy Immunotherapy revenue grew 18% to ₹214 crore, while EBITDA increased 5% to ₹66 crore, with the company expanding the overall market by increasing customer awareness as the sole supplier of Venom in the US. The CDMO Sterile Injectables business reported a 34% rise in revenue to ₹496 crore, supported by incremental revenue from Line 3 at its Spokane facility, with EBITDA standing at ₹45 crore and margins lower YoY due to negligible third-party revenues and higher operating expenses including incremental remediation cost at Montreal facility.
Shares of Jubilant Pharmova Limited were trading at ₹908 on BSE as compared to the previous close, with the stock hitting an intraday low of ₹908 and declining nearly 6% after the company reported the Q1 results. The total number of shares traded during the day was 22,357 in over 1,321 trades, with net turnover of ₹213.50 crore. The market response reflects investor concerns over the significant profit decline despite strong revenue growth, with the stock showing weakness following the earnings announcement. The company's market capitalisation stands at ₹15,318.07 crore, and the stock's current trading level shows it is 18.77% below its 52-week high of ₹1,183.90 and 22.7% above its 52-week low of ₹783.75. Looking ahead, the company expects the revenue to reach 2x from FY24 to FY30, with EBITDA margin expected between 23% to 25% by FY30.
